Antimicrobial lipids: Novel innate defense molecules are elevated in sinus secretions of patients with chronic rhinosinusitis

American Journal of Rhinology and Allergy

Volumn 24, Issue 2, 2010, Pages 99-104

  Lee, Jivianne T ^a,b   Jansen, Mike ^c   Yilma, Abebayehu N ^c   Nguyen, Angels ^c   Desharnais, Robert ^c   Porter, Edith ^c  

^a Orange County Sinus Institute   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CALIFORNIA STATE UNIVERSITY   (United States)

Author keywords

Antimicrobial; Cholesteryl; Chronic; Esters; Immunity; Innate; Lipids; Rhinosinusitis

Indexed keywords

ALPHA DEFENSIN; AMIDE; ANTIBIOTIC AGENT; ANTIMICROBIAL LIPID; CHOLESTEROL ESTER; DEFENSIN 1; DEFENSIN 2; DEFENSIN 3; LIPID; STEROID; UNCLASSIFIED DRUG;

ARTICLE; CHRONIC SINUSITIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; EXTRACTION; HUMAN; INNATE IMMUNITY; LIPID COMPOSITION; MAXILLARY SINUS; NEUTROPHIL; NOSE SECRETION; PURIFICATION; QUANTITATIVE ANALYSIS; REVERSED PHASE LIQUID CHROMATOGRAPHY; WESTERN BLOTTING;

ALPHA-DEFENSINS; ANTI-INFECTIVE AGENTS; BIOLOGICAL MARKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHRONIC DISEASE; HUMANS; IMMUNITY, MUCOSAL; LIPIDS; MUCOCILIARY CLEARANCE; NASAL LAVAGE FLUID; RHINITIS; SINUSITIS;

EID: 77950891508     PISSN: 19458924     EISSN: 19458932     Source Type: Journal    
DOI: 10.2500/ajra.2010.24.3444     Document Type: Article

References (43)

1. Ganz T. Defensins: Antimicrobial peptides of innate immunity. Nature 3:710-720, 2003. (Pubitemid 41070812)
2. Ganz T. Antimicrobial polypeptides. J Leukoc Biol 75:34-38, 2004.
3. Medzhitov R, and Janeway C Jr. Innate immunity. N Engl J Med 343:338-344, 2000.
4. Medzhitov R, and Janeway C Jr. Innate immune recognition: Mechanisms and pathways. Immunol Rev 173:89-97, 2000. (Pubitemid 30095213)
5. Ooi EH, Wormald PJ, and Tan LW. Innate immunity in the paranasal sinuses: A review of nasal host defenses. Am J Rhinol 22:13-19, 2008
6. McCormack F. New concepts in collectin-mediated host defense at the air-liquid interface of the lung. Respirology 11:s7-s10, 2006.
7. Vandermeer J, Sha Q, Kane AP, et al. Innate immunity of the sinonasal cavity: Expression of messenger RNA for complement cascade components and toll-like receptors. Arch Otolaryngol Head Neck Surg 130:1374-1380, 2004. (Pubitemid 39603298)
8. Singh PK, Tack BF, McCray PB, et al. Synergistic and additive killing by antimicrobial factors found in human airway surface liquid. Am J Physiol Lung Cell Mol Physiol 279:L799-L805, 2000.
9. Cole AM, Dewan P, and Ganz. Innate antimicrobial activity of nasal secretions. Infect Immun 67:3267-3275, 1999.
10. Cole AM, Liao J, Stuchlik O, et al. Cationic polypeptides are required for antibacterial activity of human airway fluid. J Immunol 169:6985-6991, 2002. (Pubitemid 36899286)
11. Nijnik A, and Hancock RE. The roles of cathelicidin LL-37 in immune defenses and novel clinical applications. Curr Opin Hematol 16:41-47, 2009.
12. Herr C, Shaykhiev R, and Bals R. The role of cathelicidin and defensins in pulmonary inflammatory diseases. Expert Opin Biol Ther 7:1449-1461, 2007. (Pubitemid 47485151)
13. Thormar H, and Hilmarsson H. The role of microbicidal lipids in host defense against pathogens and their potential as therapeutic agents. Chem Phys Lipids 150:1-11, 2007. (Pubitemid 47538552)
14. Do TQ, Moshkani S, Castillo P, et al. Lipids including cholesteryl linoleate and cholesteryl arachidonate contribute to the inherent antibacterial activity of human nasal fluid. J Immunol 181:4177-4187, 2008.
15. Drake DR, Brogden KA, Dawson DV, et al. Antimicrobial lipids at the skin surface. J Lipid Res 49:4-11, 2008.
16. Tollin M, Bergsson G, Kai-Larsen Y, et al. Vernix caseosa as a multicomponent defense system based on polypeptides, lipids, and their interactions. Cell Mol Life Sci 62:2390-2399, 2005. (Pubitemid 41500555)
17. Thormar H, Isaacs CE, Brown HR, et al. Inactivation of enveloped viruses and killing of cells by fatty acids and monoglycerides. Antimicrob Agents Chemother 31:27-31.
18. Isaccs CE, Kashyap S, Heird WC, et al. Antiviral and antibacterial lipids in human milk and infant formula feeds. Arch Dis Child 65:861-864, 1990. (Pubitemid 20232904)
19. Isaacs CE, Litov RE, Marie P, and Thormar H. Addition of lipases to infant formulas produces antiviral and antibacterial activity. J Nutr Biochem 3:304-308, 1992.
20. Isaacs CE, Litov RE, and Thormar H. Antimicrobial activity of lipids added to human milk, infant formulas, and bovine mild. J Nutr Biochem 6:362-366, 1995.
21. Isaacs CE. Antimicrobial function of milk lipids. Adv Nutr Res 10: 271-285, 2001.
22. Sun CQ, O'Connor CJ, and Roberton Am. The antimicrobial properties of milkfat after partial hydrolysis by calf pregastric lipase. Chem Biol Interact 140:185-188, 2002.
23. Sprong RC, Hulstein MF, and van der Meer R. Bactericidal activities of milk lipids. Antimicrob Agents Chemother 45:1298-1301, 2001.
24. Rosenfeld R, Andes D, Bhattacharyya N, et al. Clinical practice guidelines: Adult sinusitis. Otolaryngol Head Neck Surg 137 (3 suppl):S1-S31, 2007. (Pubitemid 47302529)
25. Bligh EG, and Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37:911-918, 1959.
26. Porter E, Yang H, Yavagal S, et al. Distinct defensin profiles in Neisseria gonorrhoeae and Chlamydia trachomatis urethritis reveal novel epithelial cell-neutrophil interactions. Infect Immun 73:4823-4833, 2005.
27. Shen B, Porter EM, Reynoso E, et al. Human defensin 5 expression in intestinal metaplasia of the upper gastrointestinal tract. J Clin Pathol 58:687-694, 2005. (Pubitemid 40956820)
28. Georgel P, Crozat K, Lauth X, et al. A toll-like receptor 2- responsive lipid effector pathway protects mammals against skin infections with gram-positive bacteria. Infect Immun 73:4512-4521, 2005. (Pubitemid 41105605)
29. German JB, and Dillard CJ. Composition, structure, and absorption of milk lipids: A source of energy, fat soluble nutrients and bioactive molecules. Crit Rev Food Sci Nutr 46:57-92, 2006.
30. Psaltis AJ, Bruhn MA, Tan LW, et al. Nasal mucosa expression of lactoferrin in patients with chronic rhinosinusitis. Laryngoscope 117: 2030-2035, 2007. (Pubitemid 350059387)
31. Ooi EH. Wormald PJ, Carney AS, et al. Human cathelicidin antimicrobial peptide is upregulated in the eosinophilic mucus subgroup of chronic rhinosinusitis patients. Am J Rhinol 21:395-401, 2007.
32. Kim ST, Cha HE, Kim DY, et al. Antimicrobial peptide LL-37 is upregulated in chronic nasal inflammatory disease. Acta Otolaryngol 123:81-85, 2003.
33. Lee SH, Kim JE, Lim HH, et al. Antimicrobial defensin peptides of the human nasal mucosa. Ann Otol Rhinol Laryngol 111:135-141, 2002. (Pubitemid 34131060)
34. Carothers DG, Graham SM, Jia HP, et al. Production of beta defensin antimicrobial peptides by maxillary sinus mucosa. Am J Rhinol 15: 175-179, 2001.
35. Ramanathan M Jr, Lee WK, Dubin MG, et al. Sinonasal epithelial cell expression of toll-like receptor 9 is decreased in chronic rhinosinusitis with polyps. Am J Rhinol 21:110-116, 2007. (Pubitemid 46231501)
36. Ramanathan M Jr, Lee WK, Spannhake EW, et al. Th2 cytokines associated with chronic rhinosinusitis with polyps down-regulate the antimicrobial immune function of human sinonasal epithelial cells. Am J Rhinol 22:115-121, 2008.
37. Lane A, Truong-Tran QA, Schleimer RP, et al. Altered expression of genes associated with innate immunity and inflammation in recalcitrant rhinosinusitis with polyps. Am J Rhinol 20:138-144, 2006.
38. Arikawa J, Ishibashi M, Kawashima M, et al. Decreased levels of sphingosine, a natural antimicrobial agent, may be associated with vulnerability of the stratum corneum from patients with atopic dermatitis to colonization by Staphylococcus aureus. J Invest Dermatol 119:433-439, 2002. (Pubitemid 35001954)
39. Freedman SD, Blanco PG, Zaman MM, et al. Association of cystic fibrosis with abnormalities in fatty acid metabolism. N Engl J Med 350:560-569, 2004.
40. Strandvik B, Gronowitz E, Enlund F, et al. Essential fatty acid deficiency in relation to genotype in patients with cystic fibrosis. J Pediatr 139:650-655, 2001. (Pubitemid 33097428)
41. Keen C, Olin AC, Edentoft A, et al. Airway nitric oxide in patients with cystic fibrosis is associated with pancreatic function, pseudomonas infection, and polyunsaturated fatty acids. Chest 131:1857-1864, 2007.
42. Coste TC, Armand M, Lebacq P, et al. An overview of monitoring and supplementation of omega 3 fatty acids in cystic fibrosis. Clin Biochem 40:511-520, 2007. (Pubitemid 46601416)
43. Martinez JG, Waldon M, Huang Q, et al. Membrane-targeted synergistic activity of docosahexaenoic acid and lysozyme against pseudomonas aeruginosa. Biochem J 419:193-200, 2009.